RESEARCH TRIANGLE PARK, N.C., May 05, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the ...

MORRISVILLE, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, disclosed the final figures resulting from its partnership with a ...

RESEARCH TRIANGLE PARK, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (SNCE), the clinical research industry-leading Metasite™, today announced that it has been honored with the ...

MORRISVILLE, N.C., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Today, Science 37, a leader in enhancing patient access to clinical trials, announced that it has received Frost & Sullivan’s 2024 Global Company ...

RESEARCH TRIANGLE PARK, N.C., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE) (the “Company” or “Science 37”), the clinical research industry’s leading MetasiteTM, today ...

Science 37 has been tapped to use its virtual clinical trial tech for phase 3 trials of Synlogic’s treatment for the rare genetic metabolic disorder phenylketonuria (PKU). Under the deal, Science 37’s ...

PLAYA VISTA, Calif.--(BUSINESS WIRE)--Science 37, a trailblazing company focused on “site-less” clinical trials, announced today the completion of a Phase 2b study for AOBiome, a clinical-stage life ...

RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite, announced today that it has acquired the life sciences platform ...

MORRISVILLE, N.C., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Science 37, the leader in expanding patient access to clinical trials, today announced it has been named a finalist for two prestigious SCOPE ...

“After an extensive review of opportunities available to Science 37, we believe that eMed provides the greatest value to our stockholders, customers, patients, and employees” said David Coman, Chief ...